Skip to main content

View full-text article in PMC

. 2017 Jan 15;9(1):4–20. doi: 10.4251/wjgo.v9.i1.4

Table 1.

Systemic treatment

Ref.	Type of tumor	Treatment	RR %	PFS (mo)	OS (mo)
Moertel et al[41]	Pancreatic	STZ	42		16.5
Moertel et al[41]	Pancreatic	STZ + 5FU	42		26
Moertel et al[39]	Poorly differentiated	CIS + ETO	18		19
Chan et al[58]	Carcinoid	TMZ + beva	0		18.8
Chan et al[58]	Pancreatic	TMZ + beva	33		41.7
Yao et al[72]	Pancreatic	Everolimus		9.7
Yao et al[72]	Pancreatic	Everolimus + octreotide		16.7
Yao et al[74]	Midgut carcinoid	Everolimus + octreotide		16.4
Yao et al[74]	Midgut carcinoid	Octreotide		11.3
Yao et al[78]	Pancreatic	Everolimus	34
Yao et al[78]	Pancreatic	Placebo	9
Yao et al[80]	Lung/GI NETs	Everolimus		11
Yao et al[80]	Lung/GI NETs	Placebo		3.9
Ahn et al[84]	Carcinoid	Pazopanib	0
Ahn et al[84]	Pancreatic	Pazopanib	21.9
Kulke et al[81]	Pancreatic	Sunitinib		11.4
Kulke et al[81]	Pancreatic	Placebo		5.5

PFS: Progression-free survival; STZ: Streptozocin; CIS: Cisplatin; ETO: Etoposide; 5FU: 5-fluorouracil; TMZ: Temozolomide; beva: Bevacizumab.